Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + delta-8-tetrahydrocannabinol
- Development stage
- Phase 1
- Lead developer
- City of Hope Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
cannabidiol + delta-8-tetrahydrocannabinol is an investigational phytocannabinoid combination being evaluated by City of Hope Medical Center for the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN). The treatment regimen, currently in a pilot clinical trial, assesses the efficacy of plant-derived cannabidiol (CBD) both as a monotherapy and in combination with delta-8-tetrahydrocannabinol (Delta-8-THC). These small molecule compounds are administered orally and are hypothesized to alleviate neuropathic symptoms such as pain, numbness, and tingling by modulating the endocannabinoid system through cannabinoid receptors CB1 and CB2, as well as potentially interacting with the 5-HT1A serotonergic receptor. The study specifically targets cancer survivors, including those treated for breast and colon cancer, who experience persistent neuropathy following chemotherapy.
- Other names
- cannabidioldelta-8-tetrahydrocannabinoldelta8-tetrahydrocannabinoldelta 8-tetrahydrocannabinolCBDDelta-8-THCDelta8-THCDelta 8-THCPhytocannabinoids
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabidiol + delta-8-tetrahydrocannabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + delta-8-tetrahydrocannabinol.